Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway
Margaret Kasner(Thomas Jefferson University), Alexander E. Perl(University of Pennsylvania), Selina M. Luger(University of Pennsylvania), James K. Mangan(UC San Diego Health System), John L. Wagner(Leipzig University), Matthew Carabasi(Thomas Jefferson University Hospital), Martin Carroll(University of Pennsylvania), Patricia Babcock(Thomas Jefferson University), Alison W. Loren(University of Pennsylvania), Emmanuel C. Besa(UCLA Medical Center), Dolores Grosso(Thomas Jefferson University), David L. Porter(Chapman University), Rosemarie Mick(University of Pennsylvania), Rosemary Hess(Thomas Jefferson University), Brittany J. Cannon(University of Pennsylvania), Neal Flomenberg(Memorial Sloan Kettering Cancer Center), Grace R. Jeschke(Georgetown University), Joanne Filicko-O’Hara(Thomas Jefferson University), Ubaldo Martinez‐Outschoorn(Thomas Jefferson University), Kristin Coffan(Abramson Center for Jewish Life), Noelle V. Frey(Hospital of the University of Pennsylvania), Elena Gitelson(Thomas Jefferson University), Önder Alpdoğan(Thomas Jefferson University), Mark A. Weiss(Thomas Jefferson University), Elizabeth O. Hexner(University of Pennsylvania), Martina DiMeglio(Thomas Jefferson University)
Cited by 3
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907